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Abstract
Background: To compare the efficacy of pregabalin and gabapentin at comparable effective dose levels in
patients with refractory partial epilepsy.
Methods: Eight randomized placebo controlled trials investigating the efficacy of pregabalin (4 studies) and
gabapentin (4 studies) over 12 weeks were identified with a systematic literature search. The endpoints of interest
were “responder rate” (where response was defined as at least a 50% reduction from baseline in the number of
seizures) and “change from baseline in seizure-free days over the last 28 days (SFD)”. Results of all trials were
analyzed using an indirect comparison approach with placebo as the common comparator. The base-case analysis
used the intention-to-treat last observation carried forward method. Two sensitivity analyses were conducted
among completer and responder populations.
Results: The base-case analysis revealed statistically significant differences in response rate in favor of pregabalin
300 mg versus gabapentin 1200 mg (odds ratio, 1.82; 95% confidence interval, 1.02, 3.25) and pregabalin 600 mg
versus gabapentin 1800 mg (odds ratio, 2.52; 95% confidence interval, 1.21, 5.27). Both sensitivity analyses
supported the findings of the base-case analysis, although statistical significance was not demonstrated. All dose
levels of pregabalin (150 mg to 600 mg) were more efficacious than corresponding dosages of gabapentin
(900 mg to 2400 mg) in terms of SFD over the last 28 days.
Conclusion: In patients with refractory partial epilepsy, pregabalin is likely to be more effective than gabapentin at
comparable effective doses, based on clinical response and the number of SFD.
Background
The primary objective of anti-epileptic therapy is to
obtain complete control of seizures while minimizing
the occurrence of adverse events and improving the
patient’s quality of life [1]. Unfortunately, a sizeable
minority (15% to 30%) of patients with partial epilepsy
are unsuccessfully treated with concurrent use of up to
three established anti-epileptic drugs [2-4]. Such patients
are candidates for adjunctive therapy with one of the
many newer drugs available for epilepsy, which tend to
be better tolerated than the commonly used first-line
therapies and have a low propensity for drug-drug inter-
actions [5]. While all of the new anti-epileptic drugs
have satisfied the requirements of regulatory authorities
by demonstrating superior efficacy relative to placebo
without undue toxicity, lack of comparative, controlled
clinical trial data precludes making a recommendation
regarding their relative merits as adjunctive therapies.
Pregabalin and gabapentin, a2-δ ligands, are both
licensed as adjunctive treatment for partial epilepsy,
however head-to-head comparisons of their efficacy and
safety have not been conducted. In the absence of direct,
prospective, comparative studies to guide medical deci-
sion-making in the adjunctive treatment of partial epi-
lepsy, alternative approaches are required to assess the
relative value of a particular intervention versus other
relevant comparators. In recent years, the role of meta-
analysis has developed substantially in medical applica-
tions [6-9] and is regarded as a well accepted method of
generating evidence in the context of medical decision-
making and cost-effectiveness modelling [10-12]. An
indirect comparison is an extension of traditional meta-
analysis and includes dose-response comparisons across
a range of interventions. Thus, an indirect comparison
o ft w oi n t e r v e n t i o n sc a nb em a d ev i aac o m m o n
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decision-makers by determining estimates of treatment
effects and their statistical significance with respect to
their capacity to induce an outcome of interest in the
absence of direct evidence [13,14]. Therefore, we con-
ducted an indirect comparison to assess the clinical
v a l u eo fa d j u n c t i v ep r e g a b a lin relative to gabapentin in
the management of patients with refractory partial epi-
lepsy, with respect to the responder rate (where
response was defined as a ≥50% reduction from baseline
in the number of seizures) and change from baseline in
seizure-free days over the last 28 days (SFD).
Methods
Identification and study selection
In order to identify relevant publications, a systematic
literature review was performed in English on the
PubMed and Thomson ISI Web of Science bibliographic
databases. For example, the pregabalin search strategy
on Pubmed was defined as follows: ((“pregabalin”[Sub-
stance Name] OR “pregabalin”[All Fields]) AND partial
[All Fields] AND (“epilepsy”[MeSH Terms] OR “epilep-
sy”[All Fields])) AND (Randomized Controlled Trial
[ptyp] AND English[lang]). Studies were then included
according to the following predetermined conditions:
1. Study design: Any randomized, double-blind,
fixed-dose, placebo-controlled trial meeting the cri-
teria for participants, interventions or outcomes
listed below.
2. Interventions: Comparisons between the following
interventions were of interest: low-dose pregabalin
(150 mg/day) versus low-dose gabapentin (900 mg/
day); mid-dose pregabalin (300 mg/day) versus mid-
dose gabapentin (1200 mg/day); and high-dose preg-
abalin (600 mg/day) versus high-dose gabapentin
(1800 mg/day). The official Summary of Product
Characteristics for gabapentin as adjunctive treat-
ment for partial epilepsy in the United States
includes doses of up to 1800 mg/day, but in most
other jurisdictions the recommended maximal daily
dosage is up to 2400 mg/day.
3. Study population: Patients with partial epilepsy
refractory to up to three established anti-epileptic
drugs.
4. Outcome measures: The two outcome measures of
interest were the responder rate and the change
from baseline in SFD.
5. Data extraction: For each selected study, details
were extracted on design, selection criteria, study
population characteristics, interventions, outcome
measures and results, which were subsequently
checked by a second reviewer.
Analysis
Figure 1 provides an overview of the analytical steps
taken to determine responder rate estimates. Dose-
response curves were estimated separately for
pregabalin and for gabapentin. Dose was treated as a
continuous variable, which has a logical interpretation
and is an accepted approach in determining a dose-
response curve [15]. Indeed, guidelines from the Inter-
national Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for
Human Use state that “study designs usually should
emphasize elucidation of the dose-response function,
not individual pairwise comparisons” [16]. The benefit
of using a dose-response estimation technique is that
information on all doses can be used to estimate a spe-
cific dose. This is particularly important for gabapentin
where the estimate for the 1800 mg response is based
on small patient numbers, hence information derived
from previous doses are also used to inform the shape
of the curve.
To compare high-dose pregabalin to high-dose gaba-
pentin, the estimated odds ratios for each dose were
compared via indirect comparisons, using placebo as the
common comparator. This type of analysis also esti-
mates the efficacy of gabapentin at the higher 2400 mg/
day by extrapolating the dose response equations, and
addresses the lack of clinical trial data at pregabalin 450
mg/day by interpolating the dose-response equations.
Imputed data for the base-case analysis was derived
from the intention-to-treat (ITT) population and used
the last observation carried forward (LOCF) method.
However, concerns exist regarding whether it is appro-
priate to use LOCF in analyses involving progressive
conditions or in situations where it may not be possi-
ble to determine whether missing data are non-ran-
dom. Specifically for epilepsy, LOCF analysis yields
seizure-free rates that are higher than the true clinical
situation [17]. Therefore, we conducted two sensitivity
analyses on the responder rate among “completer”
populations to assess the robustness of the compari-
sons arising in the base-case analysis (i.e., pregabalin
150 mg/day versus gabapentin 900 mg/day, pregabalin
300 mg/day versus gabapentin 1200 mg/day and prega-
balin 600 mg/day versus gabapentin 1800 mg/day).
The first sensitivity analysis (termed the “analysis of
completers”) included only those patients who com-
pleted the clinical trials, and from this dataset, respon-
ders were identified. The second sensitivity analysis
(termed the “analysis of responders”) was akin to an
ITT “missing equals failure” analysis whereby the data-
set was edited in such a way that those patients who
did not complete the clinical trials were classified as
non-responders.
Delahoy et al. BMC Neurology 2010, 10:104
http://www.biomedcentral.com/1471-2377/10/104
Page 2 of 11Responder rates and logistic regression
Logistic regression analyses were used to model dose-
response curves. For each drug, the odds ratio (vs. pla-
cebo) was modelled as a function of the drug dose.
Based on exploratory analyses of the crude odds ratios
(Figures 2 and 3), it was found that the log-odds ratio
was a linear function of the log dosage for both drugs.
Such a dose-response relationship can thus be modelled
using the following logistic regression equation:
log odds log dose () =+ () +   P (1)
Here, odds is taken to mean p/(1-p)w h e r ep is the
probability of achieving a response, while P is an indica-
tor variable set at 1 for placebo and 0 for the active
treatment groups.
This estimation approach enabled active doses to have
a different slope and gradient than placebo, while pro-
ducing both estimates within the same equation without
excluding placebo. Odds ratios along with corresponding
95% confidence intervals (CIs) were reported for each
dose of each drug versus placebo. That is, pregabalin
doses versus placebo from pregabalin trials and gaba-
pentin doses versus placebo from gabapentin trials.
Indirect comparisons of pregabalin and gabapentin
were performed on the placebo-adjusted results of these
direct comparisons. By only comparing the placebo-
adjusted effects, this method of adjusted indirect com-
parison may preserve randomization and account for
different baseline risks and other prognostic factors for
participants in different trials [13].
The log odds ratio for the indirect comparison
between pregabalin and gabapentin was obtained by
subtracting the log odds ratios of pregabalin versus pla-
cebo, from the log odds ratios of gabapentin versus
placebo.
Since the log odds ratios of pregabalin versus placebo
and gabapentin versus placebo were estimated from
Figure 1 Flow chart for analysis of responders. CI = confidence interval; GBP = gabapentin; PGB = pregabalin.
Figure 2 Dose-response curves for pregabalin and gabapentin for response (base-case analysis). The 450 mg pregabalin and 2400 mg
gabapentin doses were not studied in any of the trials; the results plotted here were calculated from the dose-response equations. CI =
confidence interval.
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Thus, the variance of the log odds ratios between prega-
balin and gabapentin was obtained by summing the var-
iances for the log odds ratios of each active treatment
versus placebo, and 95% CIs were constructed from
these variances.
Odds ratios for the indirect comparisons are presented
on the original scale by taking the exponential of the
estimate of the log odds ratio and bounds of the 95% Cl
for the log odds ratio. For ease of interpretation odds
ratios were converted to relative risk (RR) using the for-
mula of Sutton et al [8].
RR
OR
Risk OR c
=
+− 11 ()
(2)
where Riskc indicates the probability of achieving a
response in the placebo group [18] and Cochrane Colla-
boration Handbook [19].
Change from baseline in seizure-free days over the last
28 days
This analysis used the same approach as the responder
analysis except that the change from baseline in SFD is
a continuous variable. That is, the same model was used
Figure 3 Dose-response curves for pregabalin and gabapentin for response (sensitivity analyses). CI = confidence interval.
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variable was change from baseline in SFD. In line with
good statistical practice, baseline SFD was included as a
covariate. Analysis of covariance techniques were used
to estimate the dose-response curve, using PROC GLM
(SAS Version 8.0). Using this model, estimates of the
treatment difference between active doses and placebo
along with 95% CIs were obtained.
Since mean treatment differences between active doses
and placebo for pregabalin and gabapentin were ana-
lyzed using separate dose response equations, the final
analyses required indirect comparison between pregaba-
lin and gabapentin for the mean difference adjusted by
the results of the direct comparisons with placebo [13].
Estimates of the mean difference and variance (obtained
from 95% CIs) were used in the adjusted indirect com-
parison. The mean difference between pregabalin and
gabapentin was obtained by subtracting the mean differ-
ence of pregabalin versus placebo from the mean differ-
ence of gabapentin versus placebo.
Since the mean difference of each active treatment
versus placebo was estimated from different studies,
they were statistically independent. Thus, the variance of
the mean difference between pregabalin and gabapentin
was obtained by adding the variances for the mean dif-
ference of each active treatment versus placebo and 95%
CIs were constructed from these variances.
Dose-response curves were estimated for the change
from baseline in SFD for pregabalin and gabapentin
separately.
Results
Eight original research articles were identified that ful-
filled the data extraction phase (Table 1). Four studies
each pertained to randomized, placebo-controlled stu-
dies of pregabalin [20-23] and gabapentin [24-27]. All
studies were Pfizer registration trials. The indirect com-
parisons in the base-case analysis involved 1911 patients,
of which 674 received placebo, 807 received pregabalin,
and 430 received gabapentin (Table 1). Table 1 also
summarizes the number of patients completing each
trial for pregabalin and gabapentin who were included
in the sensitivity analyses. Most studies randomized an
equal proportion of men and women, and most patients
were white. In the gabapentin studies, the mean age
range was 30 to 39 years. The median range of epilepsy
duration across the studies was 17 to 23 years, and the
median range for baseline seizure rate was ≥4t o1 3p e r
28 days. Overall, 51% to 68% of patients were on two
concomitant anti-epileptic drugs and 0.3% to 3.0% were
reported to be on three. The mean age range (36 to 41
years) in the pregabalin studies was narrower than in
the gabapentin studies. The reported mean range of epi-
lepsy duration across the studies was 23 to 27 years, and
the median range for baseline seizure rate was 9 to 12
per 28 days. Relative to the gabapentin studies, the
range for the proportion of patients on two concomitant
anti-epileptic drugs was slightly lower in the pregabalin
studies (48% to 51%) but the range for the proportion of
patients on three concomitant anti-epileptic drugs was
far higher (19% to 30%). Given also that around 1% of
patients were on more than three concomitant anti-epi-
leptic drugs in the pregabalin studies, it is conceivable
that the pregabalin cohort had more severe refractory
epilepsy than the gabapentin cohort.
Logistic regression analysis of ≥50% reduction in baseline
seizures: Base-case analysis (ITT LOCF)
In the base-case analysis, each dose of pregabalin was
significantly different from placebo, with the magnitude
o ft h ed i f f e r e n c ei n c r e a s i n gw i t hd o s e( T a b l e2a n dF i g -
ure 2). Odds ratios resulting from these comparisons
were converted to relative risks using the Sutton for-
mula, assuming a placebo response rate of 10%, which
was the observed placebo response rate of the four stu-
dies when combined (i.e., 37 of 367 placebo patients
responded). Patients with refractory epilepsy who
received adjunctive high-dose pregabalin (600 mg/day)
were at least four times more likely to attain a ≥50%
reduction in baseline seizures patients receiving placebo
(RR, 4.63; 95% CI, 3.72, 5.58) (Table 2).
Similar to pregabalin, each dose of gabapentin was sig-
nificantly different from placebo, with the magnitude of
t h ed i f f e r e n c ei n c r e a s i n gw i t hd o s e( T a b l e2a n dF i g u r e
2). The risk for patients attaining a ≥50% reduction in
baseline seizures associated with adjunctive high-dose
gabapentin (2400 mg/day) was 2.82 times that of pla-
cebo. However, Figure 2 shows a greater gradient for
the dose-response curve for pregabalin than for gaba-
pentin, indicating greater incremental efficacy with
higher doses of pregabalin than that attained with corre-
sponding doses of gabapentin. Although there were
overlapping 95% CIs between the pregabalin 300 mg
and gabapentin 1200 mg dose levels, and between the
pregabalin 600 mg and gabapentin 1800 mg dose levels,
statistical significance in favor of pregabalin at these
levels was indicated, and was confirmed by the indirect
comparison described below [28].
Table 2 summarizes the indirect comparison for the
odds ratio comparing pregabalin with gabapentin at
each of their respective dose levels. Although there was
a greater proportion of responders using pregabalin 150
mg than gabapentin 900 mg, this difference was not sta-
tistically significant. However the differences between
pregabalin 300 mg and gabapentin 1200 mg were statis-
tically significantly different in favor of pregabalin.
There was also a statistically significant difference in
favor of pregabalin 600 mg versus gabapentin 1800 mg.
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mg had a 68% and 119% greater response rate than
those receiving gabapentin 1200 mg and 1800 mg,
respectively.
Analysis of completers
These datasets were restricted to those patients who
completed the clinical trials and from this completer
patient population, responders were identified. The per-
centage of patients discontinuing the trials was greater
at the higher doses of pregabalin than gabapentin trials.
In addition, a greater percentage of placebo patient
withdrew from the pregabalin than gabapentin trials.
T h eo d d sr a t i o sa n d9 5 %C I sd e r i v e df r o mt h ep r e g a -
balin and gabapentin dose-response curves among com-
pleters are summarized in Table 3. As in the base-case
analysis, each dose of pregabalin and gabapentin was
significantly different from placebo, and the magnitude
of their effects increase with dose. The CIs around the
point estimates are marginally wider, reflecting the
smaller patient population. As fewer patients discontin-
ued in the gabapentin trials, it is to be expected that the
results are largely unchanged. Conversely, the magnitude
of the odds ratios for pregabalin 150 mg and pregabalin
300 mg versus placebo are lower when the patients who
discontinued the trial are removed from the analysis,
Table 1 Summary of the multicenter, double-blind, randomized placebo-controlled trials included in the base-case and
sensitivity analyses
Individual Studies
Pregabalin Trials Daily Dose
(Titration Period)
No. of Patients Gabapentin Trials Daily Dose
(Titration Period)
No. of Patients
ITT Completers ITT Completers
Beydoun et al 2005 [21]
(Study 1008-009)
600 mg (1 week) 214 156 UK Gabapentin Study Group, 1990 [27]
(Study 877-210P)
1200 mg (2 weeks) 61 54
Placebo 98 81 Placebo 66 61
Arroyo et al 2004 [20]
(Study 1008-011)
150 mg (3 days) 99 88 The US Gabapentin Study Group No. 5,
1993 [26] (Study 945-5)
d
1200 mg (2-3
days)
101 95
600 mg (1 week) 92 69 1800 mg (2-3
days)
54 53
Placebo 96 84 Placebo 98 96
French et al 2003 [23]
(Study 1008-034)
a,b
150 mg 86 81 Anhut et al 1994 [24] (Study 945-6) 900 mg (2 days) 109 100
300 mg 90 71
600 mg 89 61 1200 mg (2 days) 52 50
Placebo 100 87 Placebo 109 100
Elger et al 2005 [22]
(Study 1008-157)
b,c
600 mg 137 80 Sivenius et al 1991 [25] (Study 945-9/10) 900 mg (2 days) 36 32
1200 mg (2 days) 17 16
Placebo 73 56 Placebo 34 30
Aggregated Studies
Treatment in Pregabalin
Trials
Daily Dose No. of Patients Treatment in Gabapentin Trials Daily Dose No. of Patients
ITT Completers ITT Completers
Placebo 367 308 Placebo 307 287
Low-Dose Pregabalin 150 mg 185 169 Low-Dose Gabapentin 900 mg 145 132
Mid-Dose Pregabalin 300 mg 90 71 Mid-Dose Gabapentin 1200 mg 231 215
High-Dose Pregabalin 600 mg 532 366 High-Dose Gabapentin 1800 mg 54 53
All studies had a 12-week double-blind maintenance phase but the durations of the titration phases were variable.
aIn addition to the doses listed above, for trial 1008-034 patients were also recruited into a 50 mg dose group. This dose was not found to be therapeutic and is
not registered for use in Australia.
bNo titration phase.
cIn addition to the doses listed above, for trial 1008-157 patients were also recruited into a titrated dose arm with total daily doses ranging from 150 mgt o6 0 0
mg, depending on individual requirement. This treatment group was not comparable with the other fixed-dose treatment groups and was excluded from the
analyses.
dIn addition to the doses listed above, for trial 945-5 patients were also recruited into a 600 mg dose group. This dose was not found to be therapeutic and is
not registered in Australia.
ITT = intention-to-treat.
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600 mg versus placebo is higher. Nevertheless, Figure 3
shows that the steep gradient for the dose-response
curve of pregabalin relative to gabapentin in the base-
case analysis was also confirmed in the analysis of
completers.
When these results are subject to indirect comparison
using placebo as the common comparator, some differ-
ences were evident between the base-case and completer
analysis. The magnitude of effects in favor of pregabalin
over gabapentin at all doses in the base-case analysis are
only retained for the high-dose comparison (i.e., prega-
balin 600 mg vs. gabapentin 1800 mg) in the completer
analysis (Table 3). Relative to odds ratios in the base-
case analysis, odds ratios in the analysis of completers
are low for pregabalin 150 mg versus gabapentin 900
mg (OR, 1.24 vs. 1.07) and pregabalin 300 mg versus
gabapentin 1200 mg (OR, 1.82 vs. 1.56). While statistical
significance is lost at the margin for the pregabalin 600
mg versus gabapentin 1800 mg comparison, the odds
ratios across the two analyses were in agreement and
therefore appear robust (OR, 2.52 vs. 2.16). A similar
finding was observed in the relative risk data, which
indicated that, among completers, adjunctive pregabalin
600 mg was associated with a 94% greater probability of
a ≥50% reduction in baseline seizures than gabapentin
1800 mg. While this relative risk was statistically insig-
n i f i c a n ta tt h em a r g i n ,i ti sc omparable to the statisti-
cally significant increased risk estimated in the base-case
analysis (RR, 2.19 vs. 1.94).
Analysis of responders
In the analysis of responders, and consistent with the
base-case analysis, each dose of pregabalin and gabapen-
tin was significantly different from placebo (Table 3).
While the magnitude of the effects of both drugs
increased with dose, Figure 3 shows that the gradient of
the dose-response curve for pregabalin is not as steep as
that observed in the base-case analysis. The gradient of
the dose-response curve for gabapentin in the analysis
of responders remained largely unchanged to that in the
Table 2 Odds ratios, relative risks and corresponding
95% confidence intervals (CI) for pregabalin and
gabapentin versus placebo, and for pregabalin versus
gabapentin in the indirect comparison using placebo as
the common comparator (base-case analysis using the
ITT LOCF approach)
Dose Comparison Odds
Ratio
95% CI Relative
Risk
a
95% CI
Pregabalin
150 mg vs. Placebo 2.75 1.73, 4.38 2.34 1.61, 3.27
300 mg vs. Placebo 4.62 3.16, 6.77 3.39 2.60, 4.29
450 mg vs. Placebo
b 6.26 4.33, 9.06 4.10 3.25, 5.02
600 mg vs. Placebo 7.77 5.32, 11.34 4.63 3.72, 5.58
Gabapentin
900 mg vs. Placebo 2.21 1.33, 3.68 1.97 1.29, 2.90
1200 mg vs. Placebo 2.54 1.64, 3.93 2.20 1.54, 3.04
1800 mg vs. Placebo 3.08 1.64, 5.81 2.55 1.54, 3.92
2400 mg vs. Placebo 3.54 1.48, 8.49 2.82 1.41, 4.85
Pregabalin vs. Gabapentin
150 mg vs. 900 mg 1.24 0.62, 2.48 1.21 0.64, 2.16
300 mg vs. 1200 mg 1.82 1.02, 3.25 1.68 1.02, 2.65
450 mg
a vs. 1800 mg 2.03 0.98, 4.23 1.84 0.98, 3.21
600 mg vs. 1800 mg 2.52 1.21, 5.27 2.19 1.19, 3.69
600 mg vs. 2400 mg
a 2.19 0.85, 5.69 1.96 0.86, 3.87
aThese relative-risk values would change with any change in assumption
regarding the placebo response rate, currently assumed to be 10%.
b450 mg pregabalin and 2400 mg gabapentin were not studied in any of the
trials; these results were calculated from the dose-response equation.
ITT = intention-to-treat; LOCF = last observation carried forward.
Table 3 Odds ratios, relative risks and corresponding
95% confidence intervals (CI) for pregabalin and
gabapentin versus placebo, and for pregabalin versus
gabapentin in the indirect comparison using placebo as
the common comparator (sensitivity analyses)
Dose Comparison Odds
Ratio
95% CI Relative
Risk
a
95% CI
Analysis of Completers
Pregabalin
150 mg vs. Placebo 2.63 1.61, 4.30 2.26 1.52, 3.23
300 mg vs. Placebo 4.23 2.82, 6.36 3.20 2.39, 4.14
600 mg vs. Placebo 6.81 4.50, 10.30 4.31 3.33, 5.34
Gabapentin
900 mg vs. Placebo 2.45 1.44, 4.17 2.14 1.38, 3.17
1200 mg vs. Placebo 2.72 1.72, 4.30 2.32 1.60, 3.23
1800 mg vs. Placebo 3.15 1.64, 6.04 2.59 1.54, 4.02
Pregabalin vs. Gabapentin
150 mg vs. 900 mg 1.07 0.52, 2.21 1.06 0.55, 1.97
300 mg vs. 1200 mg 1.56 0.84, 2.87 1.48 0.85, 2.42
600 mg vs. 1800 mg 2.16 1.00, 4.68
b 1.94 1.00, 3.42
Analysis of Responders
Pregabalin
150 mg vs. Placebo 2.85 1.76, 4.63 2.41 1.64, 3.40
300 mg vs. Placebo 3.60 2.41, 5.37 2.86 2.11, 3.74
600 mg vs. Placebo 4.54 3.04, 6.77 3.35 2.52, 4.29
Gabapentin
900 mg vs. Placebo 2.34 1.38, 3.96 2.06 1.33, 3.06
1200 mg vs. Placebo 2.69 1.71, 4.24 2.30 1.60, 3.20
1800 mg vs. Placebo 3.28 1.72, 6.28 2.67 1.60, 4.11
Pregabalin vs. Gabapentin
150 mg vs. 900 mg 1.22 0.60, 2.49 1.19 0.63, 2.17
300 mg vs. 1200 mg 1.34 0.73, 2.45 1.30 0.75, 2.14
600 mg vs. 1800 mg 1.38 0.65, 2.96 1.33 0.67, 2.47
aThese relative-risk values would change with any change in assumption
regarding the placebo response rate, currently assumed to be 10%.
bNot significant (rounded up to 1.00).
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abalin 300 mg and 600 mg dose levels were lower than
those calculated in the base-case analysis, and both dose
levels were accompanied by fairly high discontinuation
rates (ranging from 21% to 42%). The gabapentin data
were not impacted to the same extent, as fewer patients
discontinued these trials (range, 2% to 12%).
When the responder data are subject to indirect com-
parison using placebo as the common comparator, there
were no statistically significant differences between preg-
abalin and gabapentin at any dose level (Table 3).
Analysis of change from baseline in seizure-free days
over the last 28 days (SFD)
Pregabalin and gabapentin (at all dose levels) were asso-
ciated with change from baseline increases in SFD rela-
tive to placebo (Table 4). On average, patients receiving
pregabalin experienced at least a 2-day increase in SFD
compared with patients receiving placebo. In compari-
son, patients receiving gabapentin experienced at most a
1.5-day increase in SFD compared with patients receiv-
ing placebo. Figure 4 shows that the dose-response
curve for pregabalin is steeper than that for gabapentin
with respect to mean difference in SFD. The number of
SFD did not increase appreciably with gabapentin dose.
The indirect comparisons shown in Table 5 suggest
that for all dose comparisons, differences in the change
from baseline in SFD were significantly greater with
pregabalin versus gabapentin. None of the 95% CIs
included zero, indicating statistical significance in favor
of pregabalin. On average, patients receiving the lowest
dose of pregabalin experienced a 1-day (0.97-day)
increase in SFD compared with patients receiving the
lowest dose of gabapentin. As the doses of both drugs
increased, so did the mean difference in SFD.
Discussion
The objective of this analysis was to utilize existing data
to compare the efficacy of pregabalin and gabapentin in
order to better inform healthcare decision-makers of the
relative benefits of the two treatments in the current
absence of direct head-to-head comparisons. A rando-
mized, double-blind, flexible-dose trial (ClinicalTrials.
gov Identifier: NCT00537940) of pregabalin versus
gabapentin as adjunctive therapy in patients with partial
seizures is ongoing although the results will not be
available until at least 2012.
Since all trials included in this analysis were placebo-
controlled, placebo was used as the common compara-
tor. Our base-case findings, based on ITT LOCF
analysis, were that 12 weeks of mid- and high-dosage
pregabalin was more efficacious than corresponding
dosages of gabapentin in terms of responder rates, and
Table 4 Adjusted means and mean difference between
pregabalin and placebo, and gabapentin and placebo,
for seizure-free days over the last 28 days
Dose Mean
Change
in SFD
S.E. Mean Difference
Between Active
and Placebo
95% CI for
Mean
Difference
Pregabalin
150 mg 5.40 0.35 2.29 1.87, 2.72
300 mg 5.71 0.36 2.61 2.12, 3.10
450 mg
a 5.90 0.36 2.80 2.28, 3.32
600 mg 6.03 0.36 2.93 2.38, 3.47
Placebo 3.10 0.39 - -
Gabapentin
900 mg 4.42 0.36 1.32 0.82, 1.82
1200 mg 4.48 0.37 1.37 0.85, 1.89
1800 mg 4.56 0.37 1.45 0.90, 2.00
2400 mg
a 4.61 0.38 1.51 0.94, 2.08
Placebo 3.10 0.38 - -
aNote that 450 mg pregabalin and 2400 mg gabapentin were not studied in
any of the trials; these results were calculated from the dose-response
equation.
CI = confidence interval; S.E. = standard error; SFD = seizure-free days over
the last 28 days.
Figure 4 Dose-response curves for pregabalin and gabapentin
for change from baseline in seizure-free days in last 28 days.
The 450 mg pregabalin and 2400 mg gabapentin doses were not
studied in any of the trials; these results were calculated from the
dose-response equations.
Table 5 Mean difference in change from baseline in
seizure-free days over the last 28 days for pregabalin
versus gabapentin from the indirect comparison using
placebo as the common comparator
Dose Comparison Mean Difference 95% CI
150 mg vs. 900 mg 0.97 0.25, 1.69
300 mg vs. 1200 mg 1.24 0.46, 2.02
450 mg
a vs. 1800 mg 1.35 0.52, 2.18
600 mg vs. 1800 mg 1.48 0.62, 2.34
600 mg vs. 2400 mg
a 1.42 0.55, 2.29
a450 mg pregabalin and 2400 mg gabapentin were not studied, thus, these
results were calculated from the dose-response equation.
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than corresponding dosages of gabapentin in terms of
SFD. A sensitivity analysis of responder rates in the
completer population confirmed the benefit of mid- and
high-dose pregabalin, respectively, over mid- and high-
dose gabapentin, although the small sample sizes meant
that the comparisons were not able to detect statistically
significant between-treatment differences. Nevertheless,
the data generated in the base-case analysis for the com-
parison between high-dose pregabalin and gabapentin
was reproduced in the analysis of completers, inferring
that pregabalin 600 mg is twice as likely to induce a
response as gabapentin 1800 mg. In the analysis of
responders, the trend in favor of pregabalin remained
but statistical separation between the two drugs was not
detected. One possible explanation for the observed effi-
cacy advantage in favor of mid- and high-dose, but not
low-dose, pregabalin relative to corresponding doses of
gabapentin, is inherent differences in the pharmacoki-
netic profiles of the two drugs. Unlike pregabalin, gaba-
pentin exhibits saturable absorption at clinically relevant
dosages resulting in non-linear pharmacokinetics
[29-32]. Less than dose proportional increases in gaba-
pentin exposure are due to a saturable absorption
mechanism mediated by a low capacity l-amino acid
transporter found only in the upper small intestine,
where gabapentin is primarily absorbed [31,33]. As the
bioavailability of gabapentin decreases proportionally as
the dose is increased, it is logical that statistical separa-
tion regarding responder rates is manifested at the mid-
and high-dose comparisons only.
Since the two relative efficacy estimates for pregabalin
and gabapentin were based on indirect comparisons,
there is a greater potential for bias than if the compari-
sons were based on a direct prospective, randomized
controlled trial comparing the two agents. Prospective,
randomized controlled trials versus placebo were
included in this indirect comparative analysis although it
is unlikely that randomization would have held in its
entirety across the studies. As a result, there was a risk
that patients assigned to the different trials were not
comparable regarding certain demographics and clinical
characteristics. Thus, in order to minimise any bias
resulting from this risk, we included in our indirect
comparison only those studies that reported and were
well matched regarding baseline patient characteristics
(e.g., gender, age, duration of disease, baseline seizure
rate). Of note, pregabalin was demonstrated to be more
efficacious than gabapentin in this analysis despite one
of the pregabalin studies including patients with an
extremely high baseline seizure rate (21 to 25 seizures
per month) [21].
Other sources of potential bias relevant to this analysis
were that the included studies used slightly different
designs to measure treatment effects, and that there was
a relatively large time span over which the studies were
conducted and published (1990 to 2005). The use of
slightly different designs to measure treatment effects is
not expected to impact on the conclusions of the analy-
sis. The timing bias is more likely to be unfavourable
for pregabalin. In particular there was significant growth
between 1990 and 2005 in the number of alternative
add-on treatments for partial epilepsy such that if
patients felt they were not adequately responding to
pregabalin then they were probably more likely to
switch to an alternative treatment option.
All three efficacy analyses used in this study provide
useful information as to the relative merits of pregabalin
and gabapentin. ITT LOCF analysis will tend to overes-
timate response rates to pharmacotherapies in partial
epilepsy trials [17], while an ITT missing equals failure
analysis on the populationm a yp r o v i d eam o r er e p r e -
sentative picture of real-world practice. However, an
ITT missing equals failure analysis can blur the differ-
ence between two treatments when comparing a more
efficacious drug associated with a high dropout rate to a
less efficacious drug associated with a low dropout rate.
While all three analyses showed that pregabalin was
numerically more efficacious than gabapentin, the statis-
tically significant differences in response rate for prega-
balin 300 mg versus gabapentin 1200 mg and pregabalin
600 mg versus gabapentin 1800 mg derived from the
base-case analysis were not achieved in the sensitivity
analyses. This observation is due in part to the reduced
numbers of patients in the completer analysis and the
inherent variability in the data. In addition, as there
were more non-completers in the placebo arm of prega-
balin than gabapentin studies, the higher non-completer
rate among pregabalin than gabapentin recipients may
suggest that study conditions (rather than the treat-
ments) played a role in premature patient withdrawal.
One reason for the higher proportion of non-completers
i nt h ep r e g a b a l i nt h a ng a b a p e n t i nt r i a l sm a yh a v eb e e n
the short titration period used to achieve target pregaba-
lin dose levels (which was one week or less in two stu-
dies and absent in the other two studies). In this regard,
the sensitivity analysis may not reflect current use of
pregabalin. As the pregabalin studies were conducted
more recently than the gabapentin studies, another rea-
son for the higher drop-out rates observed in the pla-
cebo arm of the pregabalin studies could be the greater
availability of alternative treatment options, as discussed
above.
The results generated by this analysis are consistent
with findings from two meta-analyses of randomized,
controlled double-blind trials, in which adjunctive prega-
balin (RR 3.56; 95% CI 2.60 to 4.87; n = 1397) and
adjunctive gabapentin (OR 1.93; 95% CI 1.37 to 2.71, n =
Delahoy et al. BMC Neurology 2010, 10:104
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vide a ≥50% reduction in baseline seizures in patients
with treatment-resistant partial epilepsy [34,35]. Consis-
tent with our indirect comparison, these meta-analyses
revealed that response rates increased with pregabalin
dose (from 150 to 600 mg/day) and gabapentin dose
(600 to 1800 mg/day), showing no evidence of an effect
plateau at the doses tested [34,35]. Based partly on the
conclusions reached by these systematic reviews [9,34,35],
current epilepsy treatment guidelines recommend that
partial epilepsy refractory to up to three anti-epileptic
agents be adjunctively treated with pregabalin [5].
Conclusions
The current analysis demonstrates that pregabalin,
administered twice or three times daily for up to 12
weeks, is likely to be a more efficacious adjunctive treat-
ment for partial epilepsy than gabapentin three times
daily. Although an indirect comparison has certain
inherent limitations, we believe that the performed ana-
lysis has relevancy for clinical decision-making in the
treatment of partial epilepsy, in particular until the
results of the direct head-to-head comparison become
available.
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